Indian Immunologicals' chikungunya, JE vaccines set for human studies
This article was originally published in Scrip
Indian Immunologicals (IIL) is developing a live attenuated chikungunya vaccine in collaboration with an institute in the US. The firm, which hopes to see a fast track regulatory approach in India for some if its products, is also upbeat about the prospects of its vaccines for Japanese encephalitis (JE) and cervical cancer.
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.